

3–6 months, more frequently in patients with advanced liver disease or following transplantation (monitoring to continue for at least 1 year after discontinuation—recurrent hepatitis may occur on discontinuation).

- **PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include banana and strawberry.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Oral solution

EXCIPIENTS: May contain Sucrose

- ▶ **Epivir** (ViiV Healthcare UK Ltd)

Lamivudine 10 mg per 1 ml Epivir 50mg/5ml oral solution | 240 ml [PoM] £39.01

Tablet

- ▶ **Epivir** (ViiV Healthcare UK Ltd)

Lamivudine 150 mg Epivir 150mg tablets | 60 tablet [PoM] £143.32
DT = £143.32

Lamivudine 300 mg Epivir 300mg tablets | 30 tablet [PoM] £157.51
DT = £157.51

- ▶ **Zeffix** (GlaxoSmithKline UK Ltd)

Lamivudine 100 mg Zeffix 100mg tablets | 28 tablet [PoM] £78.09
DT = £74.17

Lamivudine with dolutegravir

30-Sep-2019

The properties listed below are those particular to the combination only. For the properties of the components please consider, lamivudine p. 689, dolutegravir p. 678.

● INDICATIONS AND DOSE

HIV-1 infection

- ▶ BY MOUTH

- ▶ Adult: 300/50 mg once daily

DOSE EQUIVALENCE AND CONVERSION

- ▶ Dose expressed as x/y mg lamivudine/dolutegravir.

- **INTERACTIONS** → Appendix 1: dolutegravir · lamivudine

- **RENAL IMPAIRMENT** Manufacturer advises avoid if creatinine clearance less than 50 mL/minute.

- **PATIENT AND CARER ADVICE**

Missed doses Manufacturer advises if a dose is more than 20 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

- **NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) decisions

SMC No. SMC2205

The *Scottish Medicines Consortium* has advised (September 2019) that lamivudine with dolutegravir (*Dovato*®) is accepted for use within NHS Scotland for the treatment of HIV-1 infection in adults and adolescents aged 12 years or older, weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

All Wales Medicines Strategy Group (AWMSG) decisions

AWMSG No. 3659

The *All Wales Medicines Strategy Group* has advised (February 2020) that lamivudine with dolutegravir (*Dovato*®) is recommended as an option for use within NHS Wales for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Tablet

- ▶ **Lamivudine with dolutegravir (non-proprietary)** ▼

Dolutegravir (as Dolutegravir sodium) 50 mg, Lamivudine 300 mg Dovato 50mg/300mg tablets | 30 tablet [PoM] £656.26

Lamivudine with tenofovir disoproxil

11-Nov-2019

The properties listed below are those particular to the combination only. For the properties of the components please consider, lamivudine p. 689, tenofovir disoproxil p. 691.

● INDICATIONS AND DOSE

HIV-1 infection in combination with other antiretroviral drugs (initiated by a specialist)

- ▶ BY MOUTH

- ▶ Adult: 300/245 mg once daily

DOSE EQUIVALENCE AND CONVERSION

- ▶ Dose expressed as x/y mg lamivudine/tenofovir disoproxil.

- **CAUTIONS** Elderly (no information available)

- **INTERACTIONS** → Appendix 1: lamivudine · tenofovir disoproxil

- **ALLERGY AND CROSS-SENSITIVITY** Manufacturer advises contra-indicated in patients with hypersensitivity to peanut or soya products.

- **RENAL IMPAIRMENT** Manufacturer advises avoid if creatinine clearance less than 50 mL/minute (consult product literature).

- **PATIENT AND CARER ADVICE**

Driving and skilled tasks Manufacturer advises patients should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 21

EXCIPIENTS: May contain Lecithin

- ▶ **Lamivudine with tenofovir disoproxil (Non-proprietary)**

Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 245 mg, Lamivudine 300 mg Lamivudine 300mg / Tenofovir disoproxil 245mg tablets | 30 tablet [PoM] £9.99 | 90 tablet [PoM] £29.97

Lamivudine with tenofovir disoproxil and doravirine

28-May-2019

The properties listed below are those particular to the combination only. For the properties of the components please consider, lamivudine p. 689, tenofovir disoproxil p. 691, doravirine p. 681.

● INDICATIONS AND DOSE

HIV-1 infection (initiated by a specialist)

- ▶ BY MOUTH

- ▶ Adult: 1 tablet once daily

DOSE ADJUSTMENTS DUE TO INTERACTIONS

- ▶ Manufacturer advises if concurrent use of moderate inducers of CYP3A4, dabrafenib, modafinil or telotristat ethyl is unavoidable, increase doravirine dose to 100 mg twice daily. Manufacturer advises increasing doravirine dose to 100 mg twice daily with rifabutin. The extra doravirine 100 mg dose should be taken approximately 12 hours after the dose of *Delstrigo*®.